<p>馬薩諸塞州劍橋市和蒙特利爾 --（商業新聞）--Repare Therapeutics Inc.（“Repare” 或 “公司”）（納斯達克：RPTX），一家臨牀階段的精準腫瘤學公司，今天宣佈與吉利德科學公司達成了一項最終資產購買協議，以收購 Repare 的聚合酶θ（Polθ）ATP 酶抑制劑 RP-3467（“吉利德協議”）。</p>
<p>“我們很高興宣佈這一交易，它將吉利德在腫瘤研究和開發方面的領先專業知識與 RP-3467 這一潛在的最佳 Polθ ATP 酶抑制劑結合在一起，” Repare 的總裁、首席執行官兼首席財務官 Steve Forte 表示。“這標誌着 Repare 今年第三筆也是最重要的投資組合交易。”</p>
<p>根據吉利德協議的條款，Repare 將獲得高達 3000 萬美元的總對價，其中包括 2500 萬美元的預付款，受制於慣例的扣留和調整，以及在完成特定技術轉讓活動後額外支付的 500 萬美元。</p>
<p>2025 年 11 月 14 日，Repare 宣佈已與 XenoTherapeutics, Inc.和 Xeno Acquisition Corp.（統稱 “Xeno”）達成了一項最終安排協議（“安排協議”），根據該協議，Xeno 將收購 Repare 所有已發行和流通的普通股（“普通股”）（“安排交易”）。根據安排協議的條款，Repare 的股東將根據安排交易結束時 Repare 的現金餘額（“安排結束時的現金淨額”）在扣除某些交易成本和未償還負債的總額後，獲得每股普通股的現金支付。</p>
<p>根據吉利德協議下應支付的對價的預付款部分，Repare 的現金餘額有所增加，因此，預計的安排結束時的現金淨額也有所增加。根據 Repare 對安排結束時現金淨額的修訂估計，目前預計每位 Repare 股東將在安排結束時獲得約 2.20 美元的現金支付。</p>
<p><strong>關於 RP-3467。</strong></p>
<p>RP-3467 是一種高效的小分子 Polθ抑制劑，是與 BRCA 突變和其他基因組改變相關的合成致死靶點。RP-3467 正在 POLAR I 期臨牀試驗中評估其安全性、藥代動力學、藥效學及其單獨或與奧拉帕利聯合使用在局部晚期或轉移性上皮卵巢癌、轉移性乳腺癌、轉移性去勢抵抗性前列腺癌或胰腺腺癌患者中的初步活性。</p>
<p><strong>關於 Repare Therapeutics Inc.</strong></p>
<p>Repare Therapeutics 是一家臨牀階段的精準腫瘤學公司，利用其專有的合成致死方法發現和開發新型治療藥物。Repare Therapeutics 開發了高度靶向的癌症療法，專注於基因組不穩定性，包括 DNA 損傷修復。有關更多信息，請訪問 www.reparerx.com，並在 X（前身為 Twitter）和 LinkedIn 上關注 @Reparerx。</p>
<p><strong>附加信息及獲取途徑</strong></p>
<p>公司已向截至 2025 年 11 月 21 日（“記錄日期”）的股東提交了一份最終代理聲明（Schedule 14A），以及其他與擬議交易相關的文件。代理聲明包含有關與 Xeno 擬議交易及相關事項的重要信息，包括關於公司將於 2026 年 1 月 16 日舉行的股東特別會議的信息，會議上將尋求股東對該交易的必要批准。<strong>公司投資者和證券持有者被敦促仔細閲讀整個代理聲明（包括任何修訂或補充），因為其中包含有關與 Xeno 擬議交易及特別會議上將投票事項的重要信息。</strong></p>
<p>公司投資者和證券持有者可以免費獲取代理聲明的副本，以及其他相關文件，這些文件包含有關公司及擬議交易的信息，包括將被納入代理聲明的材料，均可在證券交易委員會（“SEC”）的網站（http://www.sec.gov）上獲取，或通過聯繫公司的投資者關係部門（電話：857-412-7018），在公司網站（https://www.reparerx.com/contact/）提交聯繫表，或訪問公司網站的投資者關係頁面（https://ir.reparerx.com/investor-relations），點擊標題為 “SEC Filings” 的鏈接。</p>
<p><strong>徵求意見的參與者</strong></p>
<p>公司及其某些董事、高級管理人員和員工可能被視為在與 Xeno 交易中向公司股東征集代理權的 “參與者”。有關公司董事和高級管理人員的身份信息，以及他們在公司證券中的直接和間接利益（通過證券持有或其他方式）已在 2025 年 12 月 12 日向美國證券交易委員會（SEC）提交的 14A 號正式代理聲明中列出。有關公司董事和高級管理人員持有公司證券的後續變動信息可以在公司網站 www.reparerx.com 或 SEC 網站 www.sec.gov 上的 3、4 和 5 號表格中找到。有關代理徵集參與者的身份以及他們在與 Xeno 交易中的直接和間接利益（通過證券持有或其他方式）的描述包含在與 Xeno 交易相關的代理聲明及其他相關材料中，這些材料已向 SEC 提交。可以從 SEC 或公司免費獲取這些文件，具體信息如前段所述。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含根據 1995 年《私人證券訴訟改革法案》和加拿大證券法定義的 “前瞻性聲明”。本新聞稿中除歷史事實陳述外的所有陳述均為 “前瞻性聲明”。這些聲明可能通過諸如 “旨在”、“預期”、“相信”、“可能”、“估計”、“期望”、“預測”、“目標”、“打算”、“可能”、“計劃”、“可能的”、“潛在的”、“尋求”、“將會” 等詞語及其變體或類似表達來識別，儘管並非所有前瞻性聲明都包含這些詞語。本新聞稿中的前瞻性聲明包括但不限於關於：公司與吉利德的交易，包括根據資產購買協議條款收到未來付款的情況及交易的潛在利益；公司與 Xeno 的交易，包括與 Xeno 安排關閉時的現金淨額、預計公司股東在安排關閉時收到的現金支付以及關於特別會議的聲明；RP-3467 的潛在治療益處；以及 POLAR 1 期臨牀試驗的進展和結果。這些前瞻性聲明基於公司截至本新聞稿日期的預期和假設。每一項前瞻性聲明都涉及風險和不確定性，可能導致公司的臨牀開發計劃、未來結果或表現與前瞻性聲明中表達或暗示的內容有實質性差異。許多因素可能導致當前預期與實際結果之間的差異，包括：公司成功追求具有吸引力條款的戰略交易的能力，或根本無法實現；在臨牀前測試和早期臨牀試驗中的成功並不確保後續臨牀試驗會產生相同結果或提供足夠的數據以證明產品候選者的有效性和安全性；宏觀經濟條件的影響，包括關税和其他貿易政策、烏克蘭衝突和中東衝突、通貨膨脹波動以及不確定的信貸和金融市場對公司的業務、臨牀試驗和財務狀況的影響；在臨牀前研究或臨牀試驗中觀察到的意外安全性或有效性數據；臨牀試驗現場激活或入組率低於預期；公司實現其合作和許可協議利益的能力；預期或現有競爭的變化；監管環境的變化；監管批准過程的不確定性和時機；以及意外的訴訟或其他爭議。本新聞稿中前瞻性聲明所表達或暗示的實際結果可能與公司在 2024 年 12 月 31 日結束的年度報告（Form 10-K）中 “風險因素” 部分以及不時向 SEC 和 AMF 提交的其他文件中識別的因素有所不同。公司明確聲明不承擔更新本聲明中包含的任何前瞻性聲明的義務，無論是由於任何新信息、未來事件、情況變化或其他原因，法律另有要求的情況除外。有關更多信息，請訪問 reparerx.com，並在 X（前 Twitter）上關注 Repare，賬號為 @RepareRx，以及在 LinkedIn 上訪問 https://www.linkedin.com/company/repare-therapeutics/。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjQ4MDA4ODZyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjQ4MDA4ODZyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251224800886/en/</p>
<p><strong>投資者關係與媒體：</strong></p>
<p>Matthew DeYoung</p>
<p>投資者關係與媒體</p>
<p>Argot Partners</p>
<p>investor@reparerx.com</p>
<p>來源：Repare Therapeutics Inc.</p>

吉利德科學

RPTX

<p>Repare Therapeutics 宣佈其 Polθ ATPase 抑制劑 RP-3467 被吉利德科學收購，交易金額最高可達 3000 萬美元。該交易包括 2500 萬美元的預付款和 500 萬美元的技術轉讓完成後的付款。此外，Repare 與 XenoTherapeutics 簽署了一項安排協議，以收購其所有普通股，股東根據修訂後的現金餘額每股獲得約 2.20 美元</p>

<p>CAMBRIDGE, Mass. &amp; MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare’s polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”).</p>
<div class="lb-trans"><p>馬薩諸塞州劍橋市和蒙特利爾 --（商業新聞）--Repare Therapeutics Inc.（“Repare” 或 “公司”）（納斯達克：RPTX），一家臨牀階段的精準腫瘤學公司，今天宣佈與吉利德科學公司達成了一項最終資產購買協議，以收購 Repare 的聚合酶θ（Polθ）ATP 酶抑制劑 RP-3467（“吉利德協議”）。</p>
</div><p>“We are pleased to announce this transaction which combines Gilead’s leading expertise in oncology research and development with RP-3467, a potential best-in-class Polθ ATPase inhibitor,” said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. “This marks the third and most significant portfolio transaction for Repare this year.”</p>
<div class="lb-trans"><p>“我們很高興宣佈這一交易，它將吉利德在腫瘤研究和開發方面的領先專業知識與 RP-3467 這一潛在的最佳 Polθ ATP 酶抑制劑結合在一起，” Repare 的總裁、首席執行官兼首席財務官 Steve Forte 表示。“這標誌着 Repare 今年第三筆也是最重要的投資組合交易。”</p>
</div><p>Under the terms of the Gilead Agreement, Repare will receive up to $30 million in total consideration, including a $25 million upfront payment, subject to customary holdbacks and adjustments, and an additional $5 million payment upon completion of specified technology transfer activities.</p>
<div class="lb-trans"><p>根據吉利德協議的條款，Repare 將獲得高達 3000 萬美元的總對價，其中包括 2500 萬美元的預付款，受制於慣例的扣留和調整，以及在完成特定技術轉讓活動後額外支付的 500 萬美元。</p>
</div><p>On November 14, 2025, Repare announced that it had entered into a definitive arrangement agreement (the “Arrangement Agreement”) with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, “Xeno”), pursuant to which Xeno will acquire (the “Arrangement Transaction”) all of the issued and outstanding common shares of Repare (the “Common Shares”). Under the terms of the Arrangement Agreement, Repare shareholders will receive a cash payment per Common Share that will be determined based upon Repare’s cash balance at closing of the Arrangement Transaction (the “Arrangement Closing”) after deducting certain transaction costs and the aggregate amount of outstanding liabilities (the “Closing Net Cash Amount”).</p>
<div class="lb-trans"><p>2025 年 11 月 14 日，Repare 宣佈已與 XenoTherapeutics, Inc.和 Xeno Acquisition Corp.（統稱 “Xeno”）達成了一項最終安排協議（“安排協議”），根據該協議，Xeno 將收購 Repare 所有已發行和流通的普通股（“普通股”）（“安排交易”）。根據安排協議的條款，Repare 的股東將根據安排交易結束時 Repare 的現金餘額（“安排結束時的現金淨額”）在扣除某些交易成本和未償還負債的總額後，獲得每股普通股的現金支付。</p>
</div><p>The upfront portion of the consideration payable under the Gilead Agreement has increased Repare’s cash balance and, therefore, has also increased the estimated Closing Net Cash Amount. Based on Repare’s revised estimate of the Closing Net Cash Amount, it is now currently estimated that each Repare shareholder will receive a cash payment of approximately US$2.20 per Common Share at the Arrangement Closing.</p>
<div class="lb-trans"><p>根據吉利德協議下應支付的對價的預付款部分，Repare 的現金餘額有所增加，因此，預計的安排結束時的現金淨額也有所增加。根據 Repare 對安排結束時現金淨額的修訂估計，目前預計每位 Repare 股東將在安排結束時獲得約 2.20 美元的現金支付。</p>
</div><p><strong>About RP-3467.</strong></p>
<div class="lb-trans"><p><strong>關於 RP-3467。</strong></p>
</div><p>RP-3467 is a highly potent, small molecule inhibitor of Polθ that is a synthetic lethality target associated with BRCA mutations and other genomic alterations. RP-3467 is being evaluated in the POLAR Phase 1 clinical trial to evaluate its safety, pharmacokinetics, pharmacodynamics and preliminary activity alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer or pancreatic adenocarcinoma.</p>
<div class="lb-trans"><p>RP-3467 是一種高效的小分子 Polθ抑制劑，是與 BRCA 突變和其他基因組改變相關的合成致死靶點。RP-3467 正在 POLAR I 期臨牀試驗中評估其安全性、藥代動力學、藥效學及其單獨或與奧拉帕利聯合使用在局部晚期或轉移性上皮卵巢癌、轉移性乳腺癌、轉移性去勢抵抗性前列腺癌或胰腺腺癌患者中的初步活性。</p>
</div><p><strong>About Repare Therapeutics Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Repare Therapeutics Inc.</strong></p>
</div><p>Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.</p>
<div class="lb-trans"><p>Repare Therapeutics 是一家臨牀階段的精準腫瘤學公司，利用其專有的合成致死方法發現和開發新型治療藥物。Repare Therapeutics 開發了高度靶向的癌症療法，專注於基因組不穩定性，包括 DNA 損傷修復。有關更多信息，請訪問 www.reparerx.com，並在 X（前身為 Twitter）和 LinkedIn 上關注 @Reparerx。</p>
</div><p><strong>Additional Information and Where to Find It</strong></p>
<div class="lb-trans"><p><strong>附加信息及獲取途徑</strong></p>
</div><p>The Company has filed and furnished to its shareholders of record the close of business on November 21, 2025 (the “Record Date”) a definitive proxy statement on Schedule 14A, as well as other relevant documents concerning the proposed transaction with Xeno. The proxy statement contains important information about the proposed transaction with Xeno and related matters, including information related to a special meeting of Shareholders to be held on January 16, 2026 by the Company seeking required approvals from the shareholders in connection with such transaction. <strong>Investors and security holders of the Company are urged to carefully read the entire proxy statement (including any amendments or supplements thereto) because it contains important information about the proposed transaction with Xeno and the matters to be voted on at the special meeting.</strong></p>
<div class="lb-trans"><p>公司已向截至 2025 年 11 月 21 日（“記錄日期”）的股東提交了一份最終代理聲明（Schedule 14A），以及其他與擬議交易相關的文件。代理聲明包含有關與 Xeno 擬議交易及相關事項的重要信息，包括關於公司將於 2026 年 1 月 16 日舉行的股東特別會議的信息，會議上將尋求股東對該交易的必要批准。<strong>公司投資者和證券持有者被敦促仔細閲讀整個代理聲明（包括任何修訂或補充），因為其中包含有關與 Xeno 擬議交易及特別會議上將投票事項的重要信息。</strong></p>
</div><p>Investors and security holders of the Company are able to obtain a free copy of the proxy statement, as well as other relevant filings containing information about the Company and the proposed transaction, including materials that will be incorporated by reference into the proxy statement, without charge, at the Securities and Exchange Commission’s (“SEC”) website (http://www.sec.gov) or from the Company by contacting the Company’s Investor Relations at (857) 412-7018, by submitting a contact form on the Company’s website at https://www.reparerx.com/contact/, or by going to the Company’s Investor Relations page on its website at https://ir.reparerx.com/investor-relations and clicking on the link titled “SEC Filings.”</p>
<div class="lb-trans"><p>公司投資者和證券持有者可以免費獲取代理聲明的副本，以及其他相關文件，這些文件包含有關公司及擬議交易的信息，包括將被納入代理聲明的材料，均可在證券交易委員會（“SEC”）的網站（http://www.sec.gov）上獲取，或通過聯繫公司的投資者關係部門（電話：857-412-7018），在公司網站（https://www.reparerx.com/contact/）提交聯繫表，或訪問公司網站的投資者關係頁面（https://ir.reparerx.com/investor-relations），點擊標題為 “SEC Filings” 的鏈接。</p>
</div><p><strong>Participants in the Solicitation</strong></p>
<div class="lb-trans"><p><strong>徵求意見的參與者</strong></p>
</div><p>The Company and certain of its directors, executive officers and employees may be deemed to be “participants” in the solicitation of proxies from the Company’s shareholders with respect to the transaction with Xeno. Information regarding the identity of the Company’s directors and executive officers, and their direct and indirect interests, by security holdings or otherwise, in the Company’s securities is set forth in the definitive proxy statement on Schedule 14A filed with the SEC on December 12, 2025. Information regarding subsequent changes to the holdings of the Company’s securities by the Company’s directors and executive officers can be found in filings on Forms 3, 4, and 5, which are available on the Company’s website at www.reparerx.com or through the SEC’s website at www.sec.gov. Additional information regarding the identity of the participants in the proxy solicitation and a description of their direct and indirect interests in the transaction with Xeno, by security holdings or otherwise, is contained in the proxy statement and other relevant materials filed with the SEC in connection with the transaction with Xeno. Copies of these documents may be obtained, free of charge, from the SEC or the Company as described in the preceding paragraph.</p>
<div class="lb-trans"><p>公司及其某些董事、高級管理人員和員工可能被視為在與 Xeno 交易中向公司股東征集代理權的 “參與者”。有關公司董事和高級管理人員的身份信息，以及他們在公司證券中的直接和間接利益（通過證券持有或其他方式）已在 2025 年 12 月 12 日向美國證券交易委員會（SEC）提交的 14A 號正式代理聲明中列出。有關公司董事和高級管理人員持有公司證券的後續變動信息可以在公司網站 www.reparerx.com 或 SEC 網站 www.sec.gov 上的 3、4 和 5 號表格中找到。有關代理徵集參與者的身份以及他們在與 Xeno 交易中的直接和間接利益（通過證券持有或其他方式）的描述包含在與 Xeno 交易相關的代理聲明及其他相關材料中，這些材料已向 SEC 提交。可以從 SEC 或公司免費獲取這些文件，具體信息如前段所述。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company’s transaction with Gilead, including the receipt of the future payments under the terms of the asset purchase agreement and the potential benefits of the transaction; the Company’s transaction with Xeno, including the Closing Net Cash at the closing of the arrangement with Xeno, the expected cash payment to be received by Company’s shareholders at the Arrangement Closing and statements regarding the special meeting; the potential therapeutic benefits of RP-3467; and the progress and results of the POLAR Phase 1 clinical trial. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s ability to successfully pursue a strategic transaction on attractive terms, or at all; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) and the Québec Autorité des Marchés Financiers (“AMF”) on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at https://www.linkedin.com/company/repare-therapeutics/.</p>
<div class="lb-trans"><p>本新聞稿包含根據 1995 年《私人證券訴訟改革法案》和加拿大證券法定義的 “前瞻性聲明”。本新聞稿中除歷史事實陳述外的所有陳述均為 “前瞻性聲明”。這些聲明可能通過諸如 “旨在”、“預期”、“相信”、“可能”、“估計”、“期望”、“預測”、“目標”、“打算”、“可能”、“計劃”、“可能的”、“潛在的”、“尋求”、“將會” 等詞語及其變體或類似表達來識別，儘管並非所有前瞻性聲明都包含這些詞語。本新聞稿中的前瞻性聲明包括但不限於關於：公司與吉利德的交易，包括根據資產購買協議條款收到未來付款的情況及交易的潛在利益；公司與 Xeno 的交易，包括與 Xeno 安排關閉時的現金淨額、預計公司股東在安排關閉時收到的現金支付以及關於特別會議的聲明；RP-3467 的潛在治療益處；以及 POLAR 1 期臨牀試驗的進展和結果。這些前瞻性聲明基於公司截至本新聞稿日期的預期和假設。每一項前瞻性聲明都涉及風險和不確定性，可能導致公司的臨牀開發計劃、未來結果或表現與前瞻性聲明中表達或暗示的內容有實質性差異。許多因素可能導致當前預期與實際結果之間的差異，包括：公司成功追求具有吸引力條款的戰略交易的能力，或根本無法實現；在臨牀前測試和早期臨牀試驗中的成功並不確保後續臨牀試驗會產生相同結果或提供足夠的數據以證明產品候選者的有效性和安全性；宏觀經濟條件的影響，包括關税和其他貿易政策、烏克蘭衝突和中東衝突、通貨膨脹波動以及不確定的信貸和金融市場對公司的業務、臨牀試驗和財務狀況的影響；在臨牀前研究或臨牀試驗中觀察到的意外安全性或有效性數據；臨牀試驗現場激活或入組率低於預期；公司實現其合作和許可協議利益的能力；預期或現有競爭的變化；監管環境的變化；監管批准過程的不確定性和時機；以及意外的訴訟或其他爭議。本新聞稿中前瞻性聲明所表達或暗示的實際結果可能與公司在 2024 年 12 月 31 日結束的年度報告（Form 10-K）中 “風險因素” 部分以及不時向 SEC 和 AMF 提交的其他文件中識別的因素有所不同。公司明確聲明不承擔更新本聲明中包含的任何前瞻性聲明的義務，無論是由於任何新信息、未來事件、情況變化或其他原因，法律另有要求的情況除外。有關更多信息，請訪問 reparerx.com，並在 X（前 Twitter）上關注 Repare，賬號為 @RepareRx，以及在 LinkedIn 上訪問 https://www.linkedin.com/company/repare-therapeutics/。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjQ4MDA4ODZyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251224800886r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251224800886/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251224800886/en/</p>
</div><p><strong>Investor Relations &amp; Media:</strong></p>
<div class="lb-trans"><p><strong>投資者關係與媒體：</strong></p>
</div><p>Matthew DeYoung</p>
<div class="lb-trans"><p>Matthew DeYoung</p>
</div><p>Investor Relations and Media</p>
<div class="lb-trans"><p>投資者關係與媒體</p>
</div><p>Argot Partners</p>
<div class="lb-trans"><p>Argot Partners</p>
</div><p>investor@reparerx.com</p>
<div class="lb-trans"><p>investor@reparerx.com</p>
</div><p>Source: Repare Therapeutics Inc.</p>
<div class="lb-trans"><p>來源：Repare Therapeutics Inc.</p>
</div>

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration | RPTX Stock News

Repare Therapeutics 宣佈吉利德科學以總對價最高達 3000 萬美元收購 Polθ ATPase 抑制劑 RP-3467 | RPTX 股票新聞